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BRIEF REPORT
Visceral adipose tissue alteration of PI3KR1 expression is associated with
gestational diabetes but not promoter DNA methylation
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Wolfgang Henrichb, and Andreas Plagemann a
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ABSTRACT
Obesity and diabetes are at an epidemic rate, as well as growing incidences of gestational diabetes
mellitus (GDM) which causes pregnancy risks, and harm in both maternal and child health. It
remains unclear which molecular mechanisms are driving the functional differences between
visceral and subcutaneous fat and how these types directly affect an individual’s health outcome.
Paired abdominal subcutaneous and omental visceral adipose tissue were collected from women
with GDM (n = 20) and with normal glucose tolerance (NGT, n = 22) during planned caesarian
section. Both groups had similar maternal age (average 32.5 years) and BMI at delivery (average
33.3 kg/m2). Adipose tissue mRNA expression analyses of insulin signalling genes: PI3KCA, PI3KR1,
IRS1 and IRS2 showed significantly decreased PI3KR1 expression (−23%) in visceral fat in GDM with
no association to promoter DNA methylation. Reduced visceral fat PI3KR1 expression appears to be
a pathogenic factor in GDM but not through altered promoter methylation.
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Overweight and obesity are enormous public health
problems leading to various deleterious downstream
health conditions. Furthermore, this prevalence of
overweight and obesity is growing in cases of preg-
nancy as well as the rising trend of gestational diabetes
mellitus (GDM) which ultimately lead to increased risk
for future health complications for mother and child
[1–8]. The distribution/relative proportion of adipose
tissue is a major determinant factor of an individual’s
metabolic health. Adipose tissue functions to store
energy, serves as important endocrine organ, and var-
ious studies have shown dysregulated fat linked to
metabolic dysfunction [9,10]. Especially, visceral adi-
pose tissue (VAT) has been linked to chronic diseases.
It remains unclear which mechanisms and, possibly,
epigenetic modifications are driving the functional dif-
ferences between visceral and subcutaneous fat, as well
as how these fat types directly influence health out-
comes, e.g. gestational diabetes.
This study is a continuation of our previously reported
research involving the gene expression and epigenetic reg-
ulation of the metabolic players, insulin receptor (IR) and
adiponectin, in this biologically/functionally relevant tissue
(maternal adipose) within pregnancy conditions such as
GDM, overweight and obesity [11,12]. Here we investigate
the possible relevance of key downstream signal pathway
factors of IR, in particular: insulin receptor substrate 1,
(IRS1); insulin receptor substrate 2, (IRS2); phosphoinosi-
tide-3-kinase subunit p85, (PI3KR1); and phosphoinosi-
tide-3-kinase alpha (PI3KCA). These transcription factors
play important roles in themetabolic actions of insulin (e.g.
glucose transport) and are essential for adipocyte differen-
tiation. Of the insulin receptor substrate family, IRS1 and
IRS2 are the twomost ubiquitously expressed and can bind
to the PI3K (especially the p85 subunit) signalling protein
[13–15]. Both PI3KR1 (regulatory subunit) and PI3KCA
(catalytic subunit) need to come together to work as an
enzyme[15]. Disruption in the PI3K-linked pathway has
been identified in obesity as a contributor to insulin resis-
tance[14]. We sought to examine the mRNA expression
levels of the aforementioned genes in both subcutaneous
and visceral adipose tissue from mothers with GDM com-
pared to pregnancies with normal glucose tolerance
(NGT). Any changes in expression were further investi-
gated with analysis of promoterDNAmethylation to deter-
mine whether this epigenetic modifier influenced/
regulated the altered gene expression.
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Materials and methods
Subject data
This research is part of the prospective observational
‘Early CHARITÉ (EaCH)’ cohort study [11,12,16].
Here, we investigated additional genes involved in the
insulin pathway on just those cases in which the opti-
mal material and factors (such as transcription, meta-
bolic and hormonal) could be measured in a complete
set in order to avoid missing data bias. This resulted in
a subgroup of the previously reported studies on adi-
ponectin and insulin receptor genes [11,12]. Twenty
women with GDM and 22 women with NGT were
prospectively recruited before scheduled Caesarean sec-
tion (CS) of singletons at the Clinic of Obstetrics of the
Charité – Universitätsmedizin Berlin, Campus
Virchow-Klinikum, Germany. Recruitment, exclusion
criteria, standardized procedures, analytical methods
etc. are described in detail elsewhere [15]. Groups
were matched for maternal age, ethnic origin, socio-
economic status (SES), parity and, in particular, pre-
pregnancy BMI. BMI was calculated with maternal
height and weight before conception and the last mea-
sured weight within 1 week prior to delivery and then
categorized according to the WHO criteria (normal
weight: 18.5–24.9 kg/m2, overweight: 25.0–29.9 kg/
m2, obese: ≥30.0 kg/m2). GDM screening was per-
formed between the 24–28th week of gestation accord-
ing to national guidelines at the time of recruitment
[17,18]. Within the GDM group, nine women were
treated by diet and eleven were treated with diet and
additional insulin therapy to achieve glycaemic control.
No oral antidiabetic drugs were administered. Further
clinical parameters such as plasma insulin, C-peptide,
glucose and homeostatic model assessment of insulin
resistance (HOMA-IR) were determined for the cases
here as described elsewhere [11,12,16,19]. Research
design and methods were conducted in accordance to
the Declaration of Helsinki, revised in 2004, and
approved by the local Ethics Committee (EA2/026/
04). Informed written consent was obtained from all
subjects.
Adipose tissue sampling
Paired maternal sample biopsies of subcutaneous adi-
pose tissue (SAT) from the abdominal anterior wall and
VAT omental samples (from the greater omentum
[20]) were obtained during CS delivery, snap frozen
in liquid nitrogen and stored at −80°C. Samples of
~200 mg in size were available in total from all subjects
investigated here.
Gene expression analyses
Total RNA was isolated from adipose tissue (100 mg)
using the RNeasy Lipid Tissue Mini Kit (Qiagen,
Hilden, Germany) according to manufacturer’s protocol.
Quantity and purity were assessed with
a spectrophotometer (NanoDrop 1000, Thermo
Scientific, Wilmington, DE, USA) and with
a Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
CA, USA). Adipose tissue RNA (300 ng) was reverse
transcribed with the iScript kit (Bio-Rad, Hercules, CA,
USA). Quantitative real-time PCR was performed in tri-
plicate using TaqMan technology (Applied Biosystems,
Waltham, MA, USA) and a 7500 instrument (Applied
Biosystems) included respective controls and quality
checks. Pre-designed exon-exon spanning TaqMan pri-
mer assays from Applied Biosystems were used (ID: IRS1:
Hs00178563_m1; IRS2: Hs00275843_s1; PIK3R1:
Hs00933163_m1; PIK3CA: Hs00907957_m1) and ampli-
fied in singleplex with the housekeeping gene peptidyl-
prolyl isomerase A (PPIA: Hs99999904_m1) [21]. Gene
expression was normalized using the 2−ΔCt method,
including correction for amplification efficiency calcu-
lated from the standard curves for each primer set
[22,23]. As in previous reports [11,12], gene expression
of PPIA showed no group differences in both VAT and
SAT. In addition to the individual genemRNA expression
levels, the net sum of PI3KR1 + PI3KCA was included
since the PI3K-‘complex’ together acts in distinct func-
tional and molecular concert at the respective pathway
downstream of IR [13,15]. The net sum of the insulin
receptor substrate family members 1 and 2 (IRS1 + IRS2)
were also, respectively, included [15].
DNA methylation analyses
Genomic DNA was extracted from 30 mg VAT,
using the Genomic DNA-Tissue kit and the Quick-
gDNA Blood kit (Zymo Research, Irvine, CA, USA),
according to manufacturer’s protocols. Bisulphite
conversions were performed using the EZ DNA
Methylation Gold kit (Zymo Research). In silico ana-
lyses revealed a CpG island at the PI3KR1 promoter
region (Chromosomal location chr5:67,511,584–
67,597,649; UCSC Genome browser on human Feb.
2009, GRCh37/hg19 assembly). The target region was
selected as the only characterized transcription factor
binding site (TFBS) PPARgamma lays within this
sequence. Methylation assays were designed with
PyroMark Assay Design Software v. 2.0 (Qiagen),
primer and assay information is as follows (5ʹ to 3ʹ-
Bisulphite converted sequence): Forward primer:
TTGTTTTGTTATTTTAGGATTAGAAGTTAT, Reverse
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biotinylated primer: AAAACCAAAAAACCCTACAA
TTCCTAATCT, sequencing primer 1: AGGTTGTAGG
AGTTAG and sequencing primer 2: GTTTATTT
TTTTATTTTTTTTTTAT (amplicon size 256 base pairs
and annealing temperature is 54°C). Pyrosequencing was
performed on amplified PCR products using the PyroMark
Q24 pyrosequencer (Qiagen). Percent methylation was
analysed across individual measured CpG sites (12 sites).
Assay reproducibility and specificity was validated using
duplicate samples, various tissue types, and methylation
scales (0–100%).
Statistical analyses
Data are presented as means ± SEM or number and
percentage. Group comparisons were analysed by
unpaired t-test or Mann-Whitney-U-test as appropriate.
Spearman’s correlation coefficients (r) were calculated to
assess associations between clinical and/or endocrine
parameters, gene expression and DNA methylation,
respectively. Partial Pearson’s coefficients correlations
(R) were used to check potential confounding effects of
maternal BMI (prepregnancy and at delivery) and
maternal age. Statistical analyses were performed with
GraphPad Prism 7.00 (GraphPad Software, San Diego,
CA, USA) and SPSS 23.0 software (IBM, Munich,
Germany). Statistical significance was set at P < 0.05.
Results
Study cohort
Maternal and birth characteristics according to the
study groups (NGT, n = 22 and GDM, n = 20) are
reported in Table 1. Maternal age and BMI at both
prepregnancy and at the time of delivery was similar
between groups. Both groups were categorized as over-
weight according to the mean prepregnancy BMI
(NGT, 26.8 and GDM, 28.4). For the GDM group,
maternal metabolic and hormonal state remained
altered (e.g. hyperinsulinemia and hyperglycaemia) at
the end of pregnancy as compared to controls (e.g.
C-peptide, insulin and glucose plasma levels).
According to HOMA-IR, women with GDM exhibited
higher insulin resistance compared to the NGT group
(GDM, 8.2 vs. NGT, 3.2, P = 0.004).
Targeted gene expression analysis of downstream
insulin signalling pathway genes
Relative mRNA expression analyses were performed in
both SAT and VAT for IRS1, IRS2, PI3KR1, and
PI3KCA. In both fat types, no significant differences
between groups were observed for IRS1, IRS2 and
PI3KCA (Figure 1). Overall, relative expression values
were similar between VAT and SAT for IRS1 and
PI3KCA. In VAT, mRNA gene expression of PI3KR1
(p85) was significantly reduced in women with GDM
(GDM: 1192 ± 49 vs. NGT: 1543.6 ± 110, P = 0.012). No
difference in PI3KR1 was observed in SAT (Figure 1).
When comparing the net-sum expression values of
PI3KCA+R1 in VAT, a significant difference was found
(GDM: 1371 ± 56 vs. NGT: 1751 ± 119, P = 0.014).
These differences resulted in −23% PI3KR1 and −22%
PI3KCA+R1 less mRNA expression in diabetic subjects
as compared to controls in VAT. In general, PI3KR1 was
more highly expressed in VAT compared to SAT.
Table 1. Maternal and birth characteristics of study cohort according to groups (NGT and GDM).
NGT GDM
n 22 20 P-value*
Maternal age (years) 32.0 ± 1.1 33.0 ± 1.0 0.55
Prepregnancy BMI (kg/m2) 26.8 ± 1.7 28.4 ± 1.5 0.20
BMI at delivery (kg/m2) 33.1 ± 1.9 33.5 ± 1.5 0.40
Blood glucose at oGTT (mg/dL)
Fasting 79.5 ± 1.7 100 ± 6.7 <0.0002
1-h 121 ± 6.3 213 ± 8.0 <0.0001
2-h 90.3 ± 4.2 166 ± 10.8 <0.0001
Area under the curve (mg/dL*h) 206 ± 8.2 346 ± 15.6 <0.0001
Maternal fasting plasma levels at delivery:
Glucose (mg/dL) 71.1 ± 2.3 85.0 ± 1.2 <0.0001
Insulin (µU/mL) 21.5 ± 3.4 40 ± 8.0 0.04
HOMA-IR 3.2 ± 0.3 8.2 ± 1.6 0.004
C-peptide (ng/mL) 2.0 ± 0.2 4.8 ± 0.6 <0.0001
Infant data:
Birth weight (g) 3365 ± 106.0 3581 ± 98.9 0.059
Relative Birth weight (g/cm) 66.4 ± 1.5 70.31 ± 1.7 0.075
Data are means ± SEM.
Abbreviations: NGT: Normal glucose tolerance, GDM: gestational diabetes mellitus, BMI: Body-mass-index, oGTT: Oral glucose tolerance test, HOMA-IR:
Homoeostatic model assessment of insulin resistance
*Statistical significant (P-value<0.05).
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DNA methylation at the PI3KR1 promoter in
visceral adipose tissue
DNA methylation analysis was performed in VAT to
investigate a possible epigenetic-mechanistic change
(according to groups) in the promoter methylation which
could alter gene expression. The overall DNAmethylation
pattern at PI3KR1 promoter was similar across VAT sam-
ples with all 12 CpG sites investigated showing lowmethy-
lation levels (<5%) (Figure 2). No significant differences
were found between groups at individual CpG sites or with
the overall mean (GDM: 1.8% vs. NGT: 1.9%; Figure 2).
Additionally, mRNA VAT expression levels did not sig-
nificantly correlate with corresponding methylation levels
at the individual CpG sites or the overall mean (CpG
overall mean: Spearman r = 0.21, P = 0.17).
Discussion
Our data further support that differences at a molecular
level occur in visceral versus subcutaneous adipose tis-
sue in the context of GDM. This is first reported
analysis of PI3KR1 mRNA expression in maternal
VAT. Disruption of PI3KR1 expression in VAT is
most likely influenced by the mother’s insulin resis-
tance and/or vice versa. This difference in expression,
further builds to our previous research showing altered
gene expression of insulin receptor and adiponectin in
maternal VAT according to GDM and speaks to the
importance of using biologically/functionally relevant
adipose tissue in building a complete maternal genomic
profile for target genes in GDM [11,12].
While PI3KR1 and the sum of PI3KR1 plus PI3KCA
were reduced in VAT of GDM patients, we found no
differences in abdominal SAT between GDM and NGT
groups in the insulin pathway players we targeted (IRS1,
IRS2, PI3KR1 and PI3KCA). This is a similar finding to
a previous study looking at mRNA expression in SAT of
women with and without polycystic ovary syndrome (a
condition also characterized by increased insulin resis-
tance) in which no differences in these genes were
observed according to groups [24]. Again speaking to
the differing roles/profiles the fat types have.
Accordingly, it should be noted that our findings apply
to abdominal subcutaneous fat and may not be represen-
tative of other body fat deposits such as buttocks, etc. The
altered mRNA levels between experimental groups may
be related to fatty acid profiles in visceral adipose tissue as
discussed by Petrus et al. [25]. Understanding how adi-
pose tissue (especially visceral) acts as a diseased organ
should enable more strategic development for prediction,
prevention and possible treatment measures, especially
concerning GDM.
The PI3K pathway is essential for various cellular func-
tions (e.g. apoptosis, cell growth, etc.) and has been well
studied for its roles in cancer biology (e.g. endometrial
cancer), especially the potential target drug/inhibitors for
therapeutic approaches [15,26,27]. However, more
research has shifted focus to the PI3K pathway’s role in
adipocyte differentiation, inflammation and insulin
Figure 1. Relative mRNA levels of IRS1, IRS2, PI3KCA and PI3KR1 in SAT (a) and VAT (b) of women with GDM vs. NGT. Relative gene
expression of insulin receptor substrate 1 and 2 (IRS1, IRS2), phosphoinositide-3-kinase alpha (PI3KCA) and phosphoinositide-3-kinase
regulatory subunit p85 (PI3KR1) was normalized to peptidylprolyl isomerase A (PPIA) in abdominal subcutaneous (SAT- a) and
visceral omental adipose tissues (VAT – b), of women with gestational diabetes mellitus (GDM; black; n = 20) vs. normal glucose
tolerant women (NGT; white; n = 22). Sum expression values of IRS1 + 2 and PI3KCA+R1 were also included. Data are means ± SEM,
shown as percentage to NGT levels. A.U., arbitrary units.* P< 0.05 (Mann-Whitney-U test). PI3KR1-VAT P = 0.012, Sum PI3KCA+R1-VAT
P = 0.014.
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sensitivity [13]. There is strong association betweenmeta-
bolic health/complications and increased risks of chronic
disease (e.g. hypertension, stroke, etc.). There are several
overlapping pathophysiological processes/factors that
PI3KR1 influences across these health conditions which
make understanding how molecular mechanisms act (e.g.
epigenetic modifications) all the more important. Despite
PI3KR1 importance in metabolic health, it is surprising
that expression and DNA methylation in VAT has not
been previously reported (Table 2). A summary of the
current molecular findings for PI3KR1 in studies invol-
ving metabolic health (e.g. GDM) is provided in Table 2.
Additionally, we therefore provide for the first time,
a DNA methylation profile across CpG sites within the
PI3KR1 promoter in VAT in the context of pregnancy,
obesity and GDM. Interestingly, no difference in DNA
methylation or correlation to mRNA was detected
across the promoter region investigated here. Within
the target DNA methylation assay is the putative per-
oxisome proliferator response element (PPRE) 2 which
was previously identified in cell culture (in vitro)
experiments with 3T3-L1 preadipocytes and was
shown to play a role in transcriptional activation of
PI3KR1 via the transcription factor binding of peroxi-
some proliferator-activated receptor gamma
(PPARgamma)[28]. Overall transcriptional regulation
is not well characterized for PI3KR1, except for the
PPARgamma site, so DNA methylation emerged as
putative regulatory factor. However, as the PPRE2
sequence does not contain any CpG sites and as methy-
lation is not altered, this lends to DNA methylation not
having a direct regulatory influence. We propose that
perhaps modifications at the next regulatory-level at the
chromatin (e.g. histone modifiers) across the PPRE
sequences could be factors in potentially opening or
closing transcription activating binding or enhancer
elements in a tissue-specific manner. Another possible
mechanistic candidate is microRNAs (miRNAs), which
can play a role in driving tissue-specific expression
patterns. Zong et al. reported miR-29b having
a regulatory influence via the PI3K signalling pathway
in a GDM rat model [29]. Although this research was
not performed in adipose tissue but in liver and in
a rodent model, it highlights the interest for identifying
Figure 2. DNA Methylation analysis in the PI3KR1 promoter region. CpG site-specific DNA methylation analyses at the phosphoinosi-
tide-3-kinase regulatory subunit p85 (PI3KR1) at the CpG island within the promoter region in the visceral omental adipose tissue
from mothers with NGT vs. GDM. Schematic illustration of the DNA methylation assay for the PI3KR1 promoter region, including
a characterized transcription factor binding site for PPARgamma (a). Percent DNA methylation at each individual CpG site
investigated (12 CpG sites) in the VAT for normal glucose tolerant (NGT; white; n = 22) vs. gestational diabetes mellitus group
(GDM; black; n = 20). (b) CpG site number is location distance from transcriptional start site (TSS). Overall mean across CpG sites is
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non-coding RNA transcripts within this locus in order
to understand the transcriptome differences between
adipose tissue types.
A limitation of our study, which should be mentioned,
is that the analyses were performed in whole tissue sam-
ples, as in other comparable studies [11,12,14,24,30–32],
and due to the initially limited sample material available,
protein expression analysis could not be performed here.
We cannot finally exclude that the reduced gene
expression of PI3KR1 in VAT of GDM patients may
be related to differences in the body fat mass and/or
distribution or could just be an epiphenomenon, rather
than a pathogenic factor. However, our finding is in
line with the former observation of IR being specifically
altered in VAT. Therefore, we suggest a specific role of
VAT insulin resistance in the pathophysiology of GDM
which should be further explored. In summary and
conclusion, VAT reduction of PI3KR1 expression
appears as specific pathogenic co-factor in GDM,
pointing to the particular role visceral obesity may
play in GDM pathophysiology. However, this is not
explainable by altered DNA promoter methylation of




GDM gestational diabetes mellitus
HOMA-IR Homoeostatic model assessment of insulin
resistance
IRS1 insulin receptor substrate 1
IRS2 insulin receptor substrate 2
NGT Normal glucose tolerance
oGTT Oral glucose tolerance test
PI3KCA phosphoinositide-3-kinase alpha
PI3KR1 phosphoinositide-3-kinase subunit p85
PPIA peptidylprolyl isomerase A
SAT Subcutaneous adipose tissue
VAT Visceral adipose tissue
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